Mycophenolate oral suspension
US12194143B2 · kind B2 · utility
0Cited by
10References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 8, 2024 |
| Grant date | Jan 14, 2025 |
| Priority date | — |
| Expiry date | Aug 8, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water, a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.